Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan for acute decompensated heart failure with reduced ejection fraction
ChiCTR1900028053Phase 4Not yet recruiting
- Sponsor
- Chongqing Kanghua Zhonglian Cardiovascular Hospital
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) and heart failure (HF) (2 arms), sponsored by Chongqing Kanghua Zhonglian Cardiovascular Hospital. Primary endpoints: Death from cardiovascular causes and Hospitalization for heart failure. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure (HF)
Beyond the preview
Go deeper on ChiCTR1900028053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028053.